Tamoxifen Citrate
Who holds supplier records for Tamoxifen Citrate? 7 organisations hold a current record for Tamoxifen Citrate: an active US FDA Type II Drug Master File or a CEP. A further 8 organisations have only historical (inactive) DMF filings. 5 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Germany (2), India (2), Italy (1), Netherlands (1) and 1 other country (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Tamoxifen Citrate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tamoxifen-citrate
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Tamoxifen Citrate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- EXCELLA GMBH AND CO KGGermanyCEP Company GMP cert on recordActive DMF 5204 · latest filing Dec 1983
- OLON SPAItalyCEP Company GMP cert on recordActive DMF 21757, 6735 · latest filing Jun 2008
- TAPI NL BVNetherlandsCEPActive DMF 5500 · latest filing Aug 1984
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 41084 · latest filing Mar 2025
- YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDChinaActive DMF 34297 · latest filing Nov 2019
- GermanyCEP Company GMP cert on record
- BO-CHEM PRIVATE LIMITEDIndiaCEPValid CEP holder (EDQM); not necessarily the manufacturer
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (5)
Certificates of Suitability on the EDQM register for Tamoxifen Citrate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 9 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| BO-CHEM PRIVATE LIMITED Mumbai | IN | CEP 2024-595 - Rev 00 Tamoxifen citrate | Oct 2026 | — |
| TAPI NL B.V. Amsterdam | NL | CEP 1999-180 - Rev 07 Tamoxifen citrate | Jul 2025 | — |
| EXCELLA GMBH & CO. KG Feucht | DE | CEP 2021-495 - Rev 03 Tamoxifen citrate, Milled A; Milled Z | Mar 2025 | Inspected Apr 2026 Germany |
| CHEMISCHE FABRIK BERG GMBH Bitterfeld-Wolfen | DE | CEP 2022-463 - Rev 01 Tamoxifen citrate, Micronised, Non-micronised [10102/3] | Sept 2024 | Inspected May 2024 Germany |
| OLON S.P.A. Rodano | IT | R2-CEP 1995-016 - Rev 05 Tamoxifen citrate | Aug 2020 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (8)
Organisations whose Type II DMFs for Tamoxifen Citrate are no longer active. These show a past filing, not current supply.
Show all 8 historical records
- China · Inactive DMF 27466 · filed Aug 2013
- YANGTZE RIVER PHARMACY GROUP JIANGSU HAI CI BIOLOGICAL PHARMACY CO LTDInactive DMF 19284 · filed Mar 2006
- Hungary · Inactive DMF 15121, 5310 · filed Oct 2000
- CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE NIHFI LTDInactive DMF 10681 · filed Dec 1993
- LACHEMA BRNOInactive DMF 9531 · filed Jan 1992
- France · Inactive DMF 5612 · filed Dec 1984
- Finland · Inactive DMF 5363 · filed Apr 1984
- FUJISAWA DEUTSCHLAND GMBHInactive DMF 5060 · filed Jun 1983
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Tamoxifen Citrate is a nonsteroidal antiestrogen that is used in the treatment of breast cancer. It acts as a selective estrogen receptor modulator that blocks estrogen effects in the breast tissue.
Chemical identity
- IUPAC name
- 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
- Canonical SMILES
- CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
- InChIKey
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N
- Synonyms
- Nolvadex API, i.c.i.46474 citrate, ici 46,474, ici-46474, kessar, nolvadex, nourytam, nsc-180973, nsc-757345, soltamox, tamofene, tamoxifeni citras
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Estrogen Agonist/Antagonist
- Mechanism of action
- Selective Estrogen Receptor Modulators
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Tamoxifen Citrate?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Tamoxifen Citrate: EXCELLA GMBH AND CO KG (Germany), OLON SPA (Italy), TAPI NL BV (Netherlands), APITORIA PHARMA PRIVATE LTD (India), YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (China), CHEMISCHE FABRIK BERG GMBH (Germany) and BO-CHEM PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Tamoxifen Citrate Drug Master Files are active?
EXCELLA GMBH AND CO KG (DMF 5204), OLON SPA (DMF 21757, 6735), TAPI NL BV (DMF 5500), APITORIA PHARMA PRIVATE LTD (DMF 41084) and YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (DMF 34297). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Tamoxifen Citrate records mean?
8 organisations have only inactive Type II DMFs for Tamoxifen Citrate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Tamoxifen Citrate have a European Certificate of Suitability?
Yes. 5 organisations hold a valid CEP for Tamoxifen Citrate on the EDQM register, including BO-CHEM PRIVATE LIMITED Mumbai (IN), TAPI NL B.V. Amsterdam (NL), EXCELLA GMBH & CO. KG Feucht (DE), CHEMISCHE FABRIK BERG GMBH Bitterfeld-Wolfen (DE) and OLON S.P.A. Rodano (IT). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Tamoxifen Citrate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Tamoxifen Citrate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.